Pancreatic cancer is an increasingly lethal cancer and is often diagnosed at an advanced stage. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic malignant tumors and is known as the "king of cancers". The degree of malignancy is very high, making diagnosis and treatment difficult. This is because pancreatic ductal adenocarcinoma tissue contains a large amount of fibrous tissue in addition to ductal epithelial cell components. The existence of fibrous tissue results in poor blood supply for pancreatic cancer, making it difficult for chemotherapy drugs to enter, so the treatment effect is not ideal. So there is a need to develop new and more effective treatments to cure this disease.
Pancreatic Cancer Antibodies We Offer
Antibodies can be used to target cancer cells and prevent tumor growth and progression. Antibodies have been widely used in malignant tumor research, such as pancreatic cancer, breast cancer, colon cancer, non-small cell lung cancer, etc. Clinical studies have shown that antibody therapy can not only effectively kill focus cells, but also activate the human immune system to improve the body's defense against cancer, while reducing treatment side effects and improving patient survival rates. The essence of antibody therapy is to use specific monoclonal antibodies synthesized in vitro to achieve the purpose of treatment by identifying, binding and eliminating disease-related antigens or disease cells expressing antigens. Alfa Cytology has extensive experience in pancreatic cancer research and can provide you with antibody products suitable for your research project.
Alfa Cytology is committed to providing customers with antibody products with strong targeting, high stability, and obvious effects for pancreatic cancer research. We can recommend the best antibody options based on our customers' needs. If you are interested in our products, please contact us for more details.
EIPA
Catalog No.: PC0082
Description: EIPA is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also enhances autophagy by inhibiting NHE3. EIPA also inhibits macropinocytosis. EIPA can be used for research on inflammation and cancer, such as gastric cancer, colon cancer, and pancreatic cancer.
c-Met inhibitor 1
Catalog No.: PC0083
Description: c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.
Myoferlin inhibitor 1
Catalog No.: PC0084
Description: Myoferlin inhibitor 1 is a novel agent against pancreatic cancer metastasis through targeting myoferlin.
Triphen diol
Catalog No.: PC0085
Description: Triphen diol is a phenolic diol derivative with excellent anticancer activity against pancreatic cancer and cholangiocarcinoma and induces pancreatic cell apoptosis through both caspase-mediated and caspase-independent mechanisms.
KRAS G12D inhibitor 5
Catalog No.: PC0086
Description: KRAS G12D inhibitor 5 is a KRAS G12D inhibitor for the potential research of pancreatic cancer.
Avotaciclib hydrochloride
Catalog No.: PC0087
Description: Avotaciclib hydrochloride is the hydrochloride form of the CDK1 inhibitor Avotaciclib (HY-137432). Avotaciclib hydrochloride can be used for some specific cancers, such as pancreatic cancer with abnormal and strong expression of CDK1.
Toripalimab
Catalog No.: PC0088
Description: Toripalimab is China’s first domestically produced anti-tumor PD-1 antibody. Toripalimab binds to PD-1 and blocks the interaction with its ligand. Toripalimab has shown preliminary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine tumors, nasopharyngeal cancer and urothelial cancer.
E3330
Catalog No.: PC0089
Description: E3330 (APX-3330) is a direct, orally active and selective inhibitor of Ape-1 (apurinic/apyrimidinic endonuclease 1)/Ref-1 (redox factor-1) redox. E3330 is able to impair tumor growth and blocks the activity of NF-κB, AP-1, and HIF-1α in pancreatic cancer. E3330 shows anticancer activities.
Minnelide
Catalog No.: PC0090
Description: Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide promotes apoptosis.
Antitumor agent-91
Catalog No.: PC0091
Description: Antitumor agent-91 is a cyclic phosphate derivative with anticancer and antiproliferative activities and has potential application in human castration-resistant prostate cancer and pancreatic cancer.
Neurotensin
Catalog No.: PC0092
Description: Neurotensin is an intestinal tridepeptide and a potent mitogen for various colorectal and pancreatic cancers with high-affinity NTRs.
RORγ antagonist 1
Catalog No.: PC0093
Description: RORγ Antagonist 1 is a potent betulinic acid derivative that is an antagonist of RORγ. RORγ antagonist 1 exhibits antiproliferative activity in a HPAF-II pancreatic cancer xenograft model. RORγ antagonist 1 inhibits the RAS/MAPK and AKT/mTORC1 pathways and induces caspase-dependent apoptosis in pancreatic cancer cells.
IGUANA-1
Catalog No.: PC0094
Description: IGUANA-1 is a potent inhibitor of ALDH1B1, a mitochondrial enzyme that promotes colorectal and pancreatic cancer. IGUANA-1 has a significant inhibitory effect on cancer cells.
KRAS G12C inhibitor 60
Catalog No.: PC0095
Description: KRAS G12C inhibitor 60 is a Kras-G12C inhibitor that can be used in the research of lung cancer, colorectal cancer, and pancreatic cancer.
Tomentosin
Catalog No.: PC0096
Description: Tomentosin is a antiphlogistic sesquiterpene lactone that can be isolated from Inula falconeri.Tomentosin induces apoptosis and inhibits proliferation, migration and invasion of pancreatic cancer cells.
Avotaciclib
Catalog No.: PC0097
Description: Avotaciclib is a potent orally active cyclin-dependent kinase 1 (CDK1) inhibitor for the treatment of locally advanced or metastatic pancreatic cancer.
Avotaciclib trihydrochloride
Catalog No.: PC0098
Description: Avotaciclib (BEY1107) triHClide is a potent, orally active cyclin-dependent kinase 1 (CDK1) inhibitor for the treatment of locally advanced or metastatic pancreatic cancer.
CT1113
Catalog No.: PC0099
Description: CT1113 is a potent USP28 and USP25 inhibitor that reduces MYC levels in vivo and exhibits anti-tumor activity in a mouse CDX model of pancreatic cancer.
Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)
Catalog No.: PC0100
Description: Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) (c(RGDfE)) is a cyclic RGD peptide that can be used as a conjugated multifunctional nanodrug delivery system to target gemcitabine to pancreatic cancer cells. Can be used in cancer research.
GSK547
Catalog No.: PC0101
Description: GSK547 (GSK'547) is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIPK1) that inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer.